Drug intelligence / Profile preview

MI078

Development stage: Phase 3
Lead developer: Nanjing Minova Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

MI078 is an investigational small molecule drug being developed for the treatment of postpartum depression. It is currently in phase II clinical trials and is administered orally in capsule form. The precise mechanism of action has not been disclosed publicly as of June 2025. The drug is being developed by Nanjing Minowei Pharmaceutical Technology and Minover (Wuxi) Pharmaceutical Technology. Clinical studies are evaluating its efficacy, safety, tolerability, pharmacokinetics, and food effects in both healthy subjects and patients with postpartum depression[1][2][3][4][5].

Beyond the preview

Go deeper on MI078.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MI078.

Explore the full profile